XBP1 activation elevates abnormal synthesis of polyunsaturated fatty acids in hepatocytes to promote liver injury during anti-tuberculosis drug metabolism
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective This study aimed to explore new mechanistic insight into the link between abnormal lipid metabolism and ATB-DILI. Methods We performed integrative analyses of RNA-Seq, ChIP-Seq, lipids mass spectrometry, in vivo and in vitro experiments, and clinical samples to identify the key pathways and molecules involved in the process of ATB-DILI. Results Our study revealed that the cellular polyunsaturated fatty acids (PUFAs) synthesis was abnormally activated in hepatocytes during anti-TB drug metabolism. The levels of phosphatidylethanolamine substrates, ferroptosis-related arachidonic acid, and key enzyme Acyl-CoA synthetase long-chain family member 4 (ACSL4) were significantly up-regulated in ATB-DILI. Further exploration indicated that this phenomenon was linked to the endoplasmic reticulum stress factor X-box binding protein 1 (XBP1). XBP1 activation significantly enhanced the synthesis of PUFAs, thereby increasing the level of lipid peroxidation and ferroptosis, ultimately resulting in ATB-DILI. Moreover, serum Apolipoprotein levels in A-IV (APOA4) and triglyceride were elevated and may serve as early warning biomarkers for ATB-DILI. Conclusions These results systematically revealed the importance of XBP1 as a therapeutic target, and clarified the feasibility of using APOA4 and triglyceride as novel early warning biomarkers for ATB-DILI.
